129 related articles for article (PubMed ID: 31358925)
1. An audit of retinal lymphoma treatment at the University of California San Francisco.
Damato B; Bever GJ; Kim DJ; Afshar AR; Rubenstein JL
Eye (Lond); 2020 Mar; 34(3):515-522. PubMed ID: 31358925
[TBL] [Abstract][Full Text] [Related]
2. Vitreoretinal lymphoma: changing trends in diagnosis and local treatment modalities at a single institution.
Turaka K; Bryan JS; De Souza S; Gordon AJ; Kwong HM; Ziemianski MC; Reddy R; Sell CH
Clin Lymphoma Myeloma Leuk; 2012 Dec; 12(6):412-7. PubMed ID: 22995952
[TBL] [Abstract][Full Text] [Related]
3. Intraocular-central nervous system lymphoma: clinical features, diagnosis, and outcomes.
Akpek EK; Ahmed I; Hochberg FH; Soheilian M; Dryja TP; Jakobiec FA; Foster CS
Ophthalmology; 1999 Sep; 106(9):1805-10. PubMed ID: 10485554
[TBL] [Abstract][Full Text] [Related]
4. Multimodal imaging characteristics in eyes with vitreoretinal lymphoma treated with intravitreal rituximab.
Rishi P; Maitra P; Das K; Rishi E; Manchegowda PT
Int Ophthalmol; 2021 Aug; 41(8):2711-2722. PubMed ID: 33834345
[TBL] [Abstract][Full Text] [Related]
5. Reduced frequency of Intravitreal methotrexate injection lowers the risk of Keratopathy in Vitreoretinal lymphoma patients.
Zhou X; Zhou X; Shi H; Lai J; Wang Q; Li Y; Chen K; Li Q; Zhou Q; Cao X; Chen B; Xiao J
BMC Ophthalmol; 2020 May; 20(1):189. PubMed ID: 32397978
[TBL] [Abstract][Full Text] [Related]
6. Tumor Control and Visual Acuity Outcomes in Vitreoretinal Lymphoma with and without Sub-Retinal Pigment Epithelium Infiltration: Analysis of 125 Eyes of 70 Patients at a Single Ocular Oncology Center.
Dalvin LA; Lim LS; Ancona-Lezama D; Mazloumi M; Chang M; Mashayekhi A; Shields CL
Ophthalmol Retina; 2019 Nov; 3(11):998-1005. PubMed ID: 31358444
[TBL] [Abstract][Full Text] [Related]
7. INTRAVITREAL MELPHALAN INJECTION AS A SECOND-LINE LOCAL THERAPY IN VITREORETINAL LYMPHOMA: Case Series.
Guneri Beser B; Demirci H
Retina; 2024 Feb; 44(2):353-359. PubMed ID: 37883576
[TBL] [Abstract][Full Text] [Related]
8. Intravitreal methotrexate for treating vitreoretinal lymphoma: 10 years of experience.
Frenkel S; Hendler K; Siegal T; Shalom E; Pe'er J
Br J Ophthalmol; 2008 Mar; 92(3):383-8. PubMed ID: 18303160
[TBL] [Abstract][Full Text] [Related]
9. A proposed protocol of intravitreal injection of methotrexate for treatment of primary vitreoretinal lymphoma.
Zhou N; Xu X; Liu Y; Wang Y; Wei W
Eye (Lond); 2022 Jul; 36(7):1448-1455. PubMed ID: 34211136
[TBL] [Abstract][Full Text] [Related]
10. Vitreoretinal presentation of secondary large B-cell lymphoma in patients with systemic lymphoma.
Salomão DR; Pulido JS; Johnston PB; Canal-Fontcuberta I; Feldman AL
JAMA Ophthalmol; 2013 Sep; 131(9):1151-8. PubMed ID: 23744124
[TBL] [Abstract][Full Text] [Related]
11. Use of intravitreal rituximab for treatment of vitreoretinal lymphoma.
Larkin KL; Saboo US; Comer GM; Forooghian F; Mackensen F; Merrill P; Sen HN; Singh A; Essex RW; Lake S; Lim LL; Vasconcelos-Santos DV; Foster CS; Wilson DJ; Smith JR
Br J Ophthalmol; 2014 Jan; 98(1):99-103. PubMed ID: 24158837
[TBL] [Abstract][Full Text] [Related]
12. Intravitreal melphalan for persistent or recurrent retinoblastoma vitreous seeds: preliminary results.
Shields CL; Manjandavida FP; Arepalli S; Kaliki S; Lally SE; Shields JA
JAMA Ophthalmol; 2014 Mar; 132(3):319-25. PubMed ID: 24407202
[TBL] [Abstract][Full Text] [Related]
13. Role of intravitreal methotrexate in the management of primary central nervous system lymphoma with ocular involvement.
Smith JR; Rosenbaum JT; Wilson DJ; Doolittle ND; Siegal T; Neuwelt EA; Pe'er J
Ophthalmology; 2002 Sep; 109(9):1709-16. PubMed ID: 12208721
[TBL] [Abstract][Full Text] [Related]
14. Clinical Characteristics of Primary Vitreoretinal Lymphoma in an Indian Population.
Mahajan S; Nijhawan R; Rajwanshi A; Karkhur S; Mulkutar S; Dogra M; Lal V; Gupta V; Gupta A
Ocul Immunol Inflamm; 2017 Oct; 25(5):633-638. PubMed ID: 27003620
[TBL] [Abstract][Full Text] [Related]
15. INTRAVITREOUS CHEMOTHERAPY FOR ACTIVE VITREOUS SEEDING FROM RETINOBLASTOMA: Outcomes After 192 Consecutive Injections. The 2015 Howard Naquin Lecture.
Shields CL; Douglass AM; Beggache M; Say EA; Shields JA
Retina; 2016 Jun; 36(6):1184-90. PubMed ID: 26630319
[TBL] [Abstract][Full Text] [Related]
16. Intravitreal chemotherapy for vitreous disease in retinoblastoma revisited: from prohibition to conditional indications.
Munier FL; Gaillard MC; Balmer A; Soliman S; Podilsky G; Moulin AP; Beck-Popovic M
Br J Ophthalmol; 2012 Aug; 96(8):1078-83. PubMed ID: 22694968
[TBL] [Abstract][Full Text] [Related]
17. Intra-arterial chemotherapy for retinoblastoma in eyes with vitreous and/or subretinal seeding: 2-year results.
Abramson DH; Marr BP; Dunkel IJ; Brodie S; Zabor EC; Driscoll SJ; Gobin YP
Br J Ophthalmol; 2012 Apr; 96(4):499-502. PubMed ID: 22053101
[TBL] [Abstract][Full Text] [Related]
18. Retinal changes of primary vitreoretinal lymphoma after intravitreal methotrexate.
Jiang T; Gu J; Liu S; Chang Q
BMC Ophthalmol; 2022 Sep; 22(1):375. PubMed ID: 36127675
[TBL] [Abstract][Full Text] [Related]
19. [Short-term efficacy of intravitreal injection of melphalan for refractory vitreous seeding from retinoblastoma].
Xue K; Ren H; Zhang R; Yuan YF; Qian J
Zhonghua Yan Ke Za Zhi; 2017 Aug; 53(8):570-574. PubMed ID: 28851196
[No Abstract] [Full Text] [Related]
20. Longitudinal observation of OCT imaging is a valuable tool to monitor primary vitreoretinal lymphoma treated with intravitreal injections of methotrexate.
Zhao H; Wang X; Mao Y; Peng X
BMC Ophthalmol; 2020 Jan; 20(1):10. PubMed ID: 31906917
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
